Cipla To Acquire 100% Of Generic Businesses In US For $550M

Subscribe to GoodReturns
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    Cipla, a global pharmaceutical company announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies.

    The two companies are InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.

    Check the company share price details and financials

    Cipla To Acquire 100% Of Generic Businesses In US For $550M
    Cipla: Quotes, News
    BSE 521.30BSE Quote7.4 (-1.42%)
    NSE 520.70NSE Quote7.55 (-1.45%)
     

    As per the agreement, the cash consideration payable for Invagen is USD 500 million and for Exelan is USD 50 million.

    The above acquisitions will strengthen the overall presence of Cipla in the US in terms of scale, revenue, manufacturing opportunities and building a wide range of product portfolio.

    The transaction is expected to be completed by end of December 2015, subject to completion of certain conditions precedent and receipt of applicable regulatory approvals including the expiration or termination of the waiting period provided for by the Hart-Scott-Rodino Antitrust Improvements Act, the company said in the press release.

    The company stocks gave up morning gains and was een trading lower by 0.58 per cent on BSE at 12.50 pm IST. It touched an intraday high of Rs 679 and low of Rs 651 during the trade.

    GoodReturns.in

    Read more about: cipla stocks
    Story first published: Friday, September 4, 2015, 12:55 [IST]
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    Get Latest News alerts from Goodreturns

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more